The benefit of the pro-apoptotic cytokine TNF-Related Apoptosis Inducing Ligand (TRAIL) vectorized by mesenchymal stem cells (MSC) has been reported in a variety of sarcomas. Using several different cell lines in vitro and two different orthotropic xenogeneic models we here originally outline how a TRAIL delivery by MSC retains a particular impact against Ewing sarcoma prompting further investigations to assess the safety of a MSC delivery and the raise of possible mechanisms of resistance.
Introduction
Ewing sarcoma (EWS), the second most common malignant bone tumor in pediatric patients after osteosarcoma, is a rare form of cancer. It is highly metastatic and causes serious disruption to bone remodeling. EWS is identified by a chromosomal translocation between the EWS gene on chromosome 22 and a member of the ETS transcription factor family, more often FLI1 on chromosome 11, leading to production of a fusion protein which behaves like an aberrant transcription factor 1 . The resulting fusion protein, EWS-FLI1, directly or indirectly modulates the expression of many genes, altering several cell functions such as cell cycle (by targeting p21/CDKN1A, Cyclin D and E, p57/KIP2, TGFα-, IGF-or MAPK signaling pathways) or apoptosis (by targeting capase3
and members of the TNFα, IGF-1 and TGFβ signaling pathways) 2 . Transformed EWS cells appear as small, round and undifferentiated, and they are involved in major disruption of bone structure, with severe osteolytic lesions.
The current therapeutic approach consists of surgery, neoadjuvant and adjuvant chemotherapy, and in some cases radiotherapy. The 5-year survival rate has barely changed in the past 30 years, and remains at around 70% for localized forms 3 . However, the rate falls drastically to around 20% for groups of metastatic patients or poor responders to chemotherapy. New avenues of research have been opened by using TNF-Related Apoptosis Inducing Ligand (TRAIL), a pro-apoptotic cytokine from the TNF superfamily. TRAIL can bind to five receptors: two death receptors -TRAIL-R1 (Death 4 cell types by activating the intrinsic apoptosis pathway, depending on the mitochondria and apoptosome. Both pathways lead to the final cleavage of pro-caspase-3 into active caspase-3 4 .
In the early 2000s, it was reported that several cell lines derived from EWS are sensitive to TRAILinduced apoptosis in vitro [5] [6] [7] . Based on these studies, xenograft models showed that recombinant human (rh) TRAIL or death receptor (DR)5 agonists can significantly reduce tumor volume, preventing osteolytic lesions and increasing animal survival 8, 9 . Early clinical trials revealed that rhTRAIL had promising effects, but its sub-optimal bioavailability due to rapid clearance prevented the introduction of rhTRAIL into clinical use 10, 11 . Of the various strategies for increasing the therapeutic effect of TRAIL, using cells carrying TRAIL looks promising [12] [13] [14] [15] [16] [17] 
Caspase 3/7 enzymatic activity
Caspase 3/7 activity was measured using an Apo-ONE® Homogeneous assay kit (Promega). Briefly, cells were lysed in RIPA buffer (10 mM Tris pH8, 1 mM EDTA, 150 mM NaCl, 1% NP40, 0.1% SDS)
containing a cocktail of protease and phosphatase inhibitors (1 mM sodium orthovanadate (Na2VO4), 1 mM phenylmethylsulforyl fluoride (PMSF), 10 mM sodium fluoride (NaF), 10 mM Nethylmaleimide (NEM), 2 μg/ml leupeptin and 1 μg/ml pepstatine) at 4°C. An equal volume of reagents was added to a white-walled 96-well plate containing protein extracts and incubated at room temperature for 16h. The fluorescence of each sample was measured in a plate-reading Tristar LB941 (Berthold technologies). The data shown concern the concentration of total protein determined with a BCA kit (Sigma, St Quentin-Fallavier, France).
In Vivo Experiments
Ewing sarcoma animal models. Four-week-old Rj:NMRI-nude mice (Janvier Labs -Le Genest-Saint- 
Statistical analyses
Each experiment was repeated independently 3 times. The results are given as a mean ± SD for in vitro experiments and a mean ± SEM for in vivo experiments. They were compared using an unpaired t test or two-way ANOVA followed respectively by the Bonferroni post-test or the Tukey's multiple comparisons test using Graph Pad Prism v6.01 software. Results with p < 0.05 were considered significant and are represented by an asterisk (*), p < 0.01 results are represented by two asterisks (**) and p < 0.001 by three asterisks (***).
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Results
Confirmation of GFP and TRAIL transduction efficiency in MSC-GFP and MSC-TRAIL. AD-MSC were transduced in a stable manner with vector encoding full-length human TRAIL (MIGR1-TRAIL-GFP) and with control vector (MIGR1-GFP). After 3 passages, fluorescent microscopy ( Figure 1A ) and cytometry analysis ( Figure 1B) confirmed that more than 98% of the transduced MSC were GFP positive. RT-qPCR analyses showed that MSC-GFP constitutively expressed negligible TRAIL mRNA levels ( Figure 1C) , with protein levels that were below the ELISA detection limit ( Figure 1D ). In 
International Journal of Cancer
We then decided to assess whether this anti-cancer effect was mediated by membrane-or soluble forms of TRAIL, or both ( Figure 3C ). Tumor cells in Boyden chambers overhanging MSC-TRAIL did not slow their proliferation when compared to tumor cells in Boyden chambers overhanging MSC-GFP (illustration for TC-71 and SK-ES-1 in Figure 3D ). These results show that a direct cell-to-cell contact between EWS cells and MSC-TRAIL is necessary for cell death to be induced, indirectly suggesting that the amount of TRAIL released by MSC-TRAIL is not enough to reduce proliferation in cell lines. 
MSC-TRAIL inhibit tumor progression when co-injected with EWS cells in vivo

International Journal of Cancer
11
GFP (Figure 4C) , the group co-injected with MSC-GFP showed a slight, though significant, acceleration in tumor growth when compared to the control group (Figure 5A, B) . Despite the protumoral effect of MSC-GFP, the injection with MSC-TRAIL controlled tumor growth and tumors were barely detectable in the MSC-TRAIL group, with a tumor volume of less than 80 mm 3 at 20 days (Figure 5A, B) . As a consequence, the survival rate increased significantly in the group co-injected with MSC-TRAIL and A-673 cells, and the mice developed significant tumor volumes only 40 days after the injection time, surviving for more than 70 days, despite the aggressiveness of the A-673 cell line ( Figure 5C ).
However, when MSC-TRAIL were injected into established tumors, only a transient significant inhibitory effect could be observed around day 5, but this did not affect animal survival (Supplementary Figure S1) . Figure 5D ). This effect remained local, as the presence of active caspase-3 was only localized around the injected MSC-TRAIL on a total histological section of the tumor (Figure 5E ). On the contrary, MSC-GFP injection did not induce apoptosis in adjacent EWS cells.
In vivo MSC-TRAIL induce apoptosis in adjacent Ewing
Discussion
The ability of TRAIL to induce tumor apoptosis and death without affecting normal cells makes it a very interesting tool for tumor therapy. However, many types of cancer remain resistant to TRAIL, including sarcomas 21, 22 . Finding relevant and diversified strategies to overcome this resistance seems to be an essential prerequisite for offering patients new therapeutic options.
MSC can be engineered to express TRAIL and a recent study has demonstrated that these cells can induce apoptosis in a variety of sarcomas (osteosarcoma, rhabdomyosarcoma, EWS) by activation of caspase-8 20 , paving the way for MSC-TRAIL-based therapies in these still deathly forms of cancer.
Here, we further confirm these findings by focusing on EWS and demonstrating that AD-MSC delivering TRAIL can induce apoptosis in a wide panel of EWS cell lines in vitro. All the cell lines considered were sensitive to apoptosis induced by MSC-TRAIL, suggesting that the extrinsic apoptosis signaling pathway is functional in all these cell lines. This appears to be in contrast with the data, suggesting that some of these lines are resistant to relatively high amounts of rhTRAIL. While this finding requires further investigation, we can currently hypothesize that MSC-TRAIL is able to induce significant clustering of death receptors at the surface of EWS cells, multiplying the downstream activation of caspase-8. A study with liposome-bound TRAIL reports that higher DR5 clustering enhances DISC formation and triggers caspase activation more efficiently than the soluble form of rhTRAIL 23 . In addition, a second TRAIL signaling pathway has recently been described, involving NFkB, MAPK, PI3K/Akt activation via binding to the same receptors, but leading to increased tumor cell proliferation, survival, migration and invasion (reviewed in 24 ). The key regulator of this kinase network is the RIPK1 protein, which binds FADD instead of caspase-8, inducing the formation of a secondary signaling complex composed of TRADD, TRAF2 and RIPK1. We can further hypothesize that rhTRAIL can activate this secondary pathway that counteracts its pro-apoptotic effect, whereas high clustering of MSC-TRAIL and death receptors may associate several caspase-8 molecules which overcome the formation of the RIPK1-TRADD-TRAF2 complex. The evidence that only direct contact 13 between EWS cells and MSC-TRAIL can induce apoptosis supports the concept that a high level of death receptor clustering is necessary for apoptosis induction via DISC formation. The need for cellto-cell contact for AD-MSC TRAIL delivery has been also reported in a cervical carcinoma cell line 18 .
However, our study is the first evidence provided in several sarcoma cell lines, indicating that a cell delivery approach for TRAIL may be far more efficient than rhTRAIL alone, indicating the need for dedicated strategies to drive MSC homing and persistence inside tumors.
A previous study showed that MSC-TRAIL can exert relevant antitumor activity against a subcutaneous xenograft model of RD-ES EWS cells 20 . However, we felt that in these neoplastic disorders so closely related to skeletal tissues, more relevant orthotopic models needed to be It has been shown that MSC expressing TRAIL were able to reduce the incidence of lung metastases in carcinoma models 15 . However, this effect was not observed in our EWS mouse models as the cells were highly aggressive with too rapid progression that was not enough to develop and observe spontaneous metastases. We therefore cannot conclude on the effect of MSC-TRAIL on the occurrence of metastases in these models, and dedicated EWS metastatic models are needed to clarify this aspect.
We also report that in one of the para-tibial orthotopic EWS model obtained with the A-673 EWS line, the MSC-GFP enhanced tumor progression, as previously described with the HeLa cell line 18 .
Several studies have reported that MSC may have the ability to promote cancer growth, particularly by increasing angiogenesis, releasing chemokines or interfering with cancer metabolism [25] [26] [27] [28] . This effect observed in osteosarcoma syngeneic and xenograft mouse models 29, 30 seems to be an obstacle to the use of MSCs as therapeutic tools in bone tumor pathologies. However, other results suggest that MSCs inhibit tumor growth, especially by inhibiting the Wnt pathway [31] [32] [33] [34] [35] . A concise review categorizes both MSC pro-or anti-tumor effects depending on different tumor types and microenvironments 36 . Therefore, understanding the conditions in which MSC may enhance tumor growth is crucial for safely developing MSCs as a therapeutic tool.
In conclusion, we have shown that AD-MSCs delivering TRAIL can counteract EWS growth both in vitro and in vivo within two different orthotopic EWS models. Efforts will now focus on solidifying the strategy in order to safely transfer MSCs as therapeutic tools for EWS, starting with deeper understanding of the conditions in which MSCs may influence tumor growth before properly defining delivery approaches. However, the use of MSC-TRAIL evidenced that a high death receptor membrane presentation is able to induce apoptosis in cell lines initially resistant to rhTRAIL in vitro.
This clustering strategy is very promising and can be conducted with more neutral TRAIL vectors, such as new TRAIL death receptor agonists capable of bind six receptors 37 .
